XIX International AIDS Conference 25 July 2012 Lee Hall, MD, PhD Chief, Parasitology & International Programs Branch Division of Microbiology & Infectious.

Slides:



Advertisements
Similar presentations
Achieving a ‘Grand Convergence’ in Global Health Chair: Richard Feachem, University of California, San Francisco Presenter: Dean Jamison, University of.
Advertisements

EARLY AND MID-CAREER DEVELOPMENT OPPORTUNITIES JACQUELINE LLOYD, MSW, PHD NIH SUMMER INSTITUTE JULY 2012 NIIDA NATIONAL INSTITUTE ON DRUG ABUSE.
Outbreak Scenario S. marcescens At a multi-disciplinary meeting on the surgical unit concerns are raised regarding a possible increase in.
HAS 3150 Chapter 10. Infectious Diseases Diseases caused by living microorganisms.
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Health Departments and Healthcare-Associated Infection Prevention Research: A New Land of Opportunity? Matthew Wise, MPH, PhD Epidemiologist, Office of.
Global Health Program Guiding Principles April 2002.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Impact evaluation Evaluate new tools Translate new knowledge into policy and implementation Knowledge gap Program implementation.
Funding research into ageing- The NH&MRC perspective Professor Judy Black.
ACGME OUTCOME PROJECT : THE PROGRAM COORDINATOR’S ROLE Jim Kerwin, MD University of Arizona.
HIV NON-INTERVENTION: A COSTLY OPTION A NEW FRAMEWORK FOR GLOBALIZATION Jeffrey D. Sachs, PhD Director, Center for International Development Galen L. Stone.
Program Collaboration and Service Integration: An NCHHSTP Green paper Kevin Fenton, M.D., Ph.D., F.F.P.H. Director National Center for HIV/AIDS, Viral.
Influenza Vaccine Development
Infections of the GI Tract November 19, 2007 NCDD Meeting Chair: Mitchell B. Cohen, MD Vice Chair: Richard S. Blumberg, MD.
Fogarty International Center: HIV Research Training Program: New Applications and Strategies Gene D. Morse, PharmD University at Buffalo AIDS International.
Colorado Department of Public Health and Environment Tuberculosis Prevention and Control Program.
Sex and Gender Some definitions.
Overview of NIDA Funding Opportunities and Grant Funding Tips Bethany Griffin Deeds, Ph.D., M.A. Deputy Chief, Epidemiology Research Branch Division of.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
MALARIA AND NEGLECTED TROPICAL DISEASES (NTDs): FINDINGS FROM THE 2012 G-FINDER REPORT.
The significance of Medical Parasitology. Prevalent infections worldwide Significant morbidity & mortality Significant impact on economic & social development.
Guidelines For Supporting ECD in the Multi-country HIV/AIDS Program for Africa.
Gustavo Aquino, MPH Associate Director for Program Integration National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Program Collaboration.
Welcome to “STD 101 in a Box” Developed by Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
Vaccine Quo Vadis? 20 July 2010 Alan Bernstein, O.C., Ph.D. Executive Director, Global HIV Vaccine Enterprise.
Myron S. Cohen, MD Protocol Chair 6 th IAS Conference, Rome, Italy July 18, 2011 HPTN 052: Summary.
 Getting Outside of the Box: Designing and Implementing Innovative Ways to Prevent Infection Willo Pequegnat, Ph.D., Salix Health Consulting/USAID Susan.
Aging in Indiana: A Golden Opportunity or Silver Tsunami Marie Beason Indiana Grantmakers Alliance.
PERSPECTIVES FROM THE FIELD DR LYDIA MUNGHERERA TASO (The Aids Support Organisation) UGANDA REVERSING THE TIDE OF TB.
The significance of Medical Parasitology
Alcohol and AIDS: A New Decade Grantsmanship Workshop XIX International AIDS Conference Rome, Italy Kendall J. Bryant, Ph.D., NIAAA Alcohol and AIDS Research.
Research Priorities & Trends for NIH in 2003 Claire T. Driscoll Director Technology Transfer Office National Human Genome Research Institute (NHGRI) Research.
Future Approaches to NIAMS Clinical Trials * As presented to the NIAMS Advisory Council on June 2, 2009.
Funded by the National Plant Diagnostic Network Hosted by the Integrated Plant Protection Center – Oregon State University.
Dr. Brian Armour Trinidad and Tobago. 2004: International Best Practice Governance Structure (UNAIDS)  14 February 2001: close to 10 yrs PANCAP  62.
Yen-Jen Sung, MD PhD Commissioner, Department of Health, Taipei City Government Infectious Disease: Prevention Strategies & Emergency Response Procedures.
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Critical Program Movement: Integration of STD Prevention with Other Programs Kevin Fenton, MD, PhD, FFPH Director National Center for HIV/AIDS, Viral Hepatitis,
Janet Heitgerd, PhD Program Evaluation Branch, Associate Chief for Science American Evaluation Association Annual Meeting November 2010 Improving the Design,
Version: 27 May 2007 New Models for Collaboration: Patients as Drivers and Partners in Neurological Research Integrating Patient Input Within the Drug.
NIH HIV/AIDS Research Priorities
HIV/AIDS Implementation Science Research Across NIH: Recent Highlights, Current Priorities, and Partners Christopher Gordon, PhD Branch Chief, Division.
State Office of AIDS Update
Prevention Solutions for the Next Generation: Highlighting Adolescent Research in the NIH HIV/AIDS Clinical Trials Networks and the Adolescent Trials Network.
Estimated number of annual AIDS cases,
Community Advocacy & Education to End Stigmatizing HIV/TB Language
Community Advisory Boards on Repeat:
Field Services and Evaluation Branch
Demonstrate and Measure the Impact of the Application of the Principles of Medical Informatics in Low-Resource Settings Gerry Douglas, PhD Assistant Professor.
Matthew R. Pincus, MD, PhD  Clinics in Laboratory Medicine 
People living with AIDS in Maine at the end of 1984
Vaccine and Infectious Disease Institute
Changes in the intestinal microbiota from adulthood through to old age
Jeffrey D. Sachs, PhD Director, Center for International Development
LSU Health Sciences Center – New Orleans Department of Microbiology, Immunology and Parasitology SPRING 2009 SEMINAR SERIES “Understanding the Mechanisms.
آموزش همسان دکتر كامبيز محضري.
J.-P. Van geertruyden  Clinical Microbiology and Infection 
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
CMI editorial report 2011 Clinical Microbiology and Infection
Matthew R. Pincus, MD, PhD  Clinics in Laboratory Medicine 
Acute schistosomiasis, a diagnostic and therapeutic challenge
New diagnostic tools in schistosomiasis
Metagenomics and probiotics
Every Mother, Every Child: Closing the Gaps in HIV Management
J.A. Pérez-Molina, F. Fernández  Clinical Microbiology and Infection 
The future of diagnostic bacteriology
National Institutes of Health
How are programmes specifically designed using collected data?
Vincent Calvez, Marc Grandadam  Clinical Microbiology and Infection 
Presentation transcript:

XIX International AIDS Conference 25 July 2012 Lee Hall, MD, PhD Chief, Parasitology & International Programs Branch Division of Microbiology & Infectious Diseases

Interactions Between NTDs & HIV Are Bidirectional 2 Neglected Tropical Diseases HIV

Some Potential Effects of NTD-HIV Coinfections  Changes in Disease Progression or Clinical Manifestations  Changes in Transmissibility  Changes in Susceptibility  Impacts on Diagnostic Sensitivity or Specificity 3

Some Potential Effects of NTD-HIV Coinfections: Research Considerations  Qualitative vs. Quantitative Changes?  What Mechanisms Are Responsible for the Changes?  Are the Changes Reversible? Preventable?  What Would Be Considered a Meaningful Effect?  Do We Have Adequate Tools to Reverse or Prevent Changes?  What Alternatives Are Available to Achieve the Desired Changes? 4

Research Opportunities: Funding Mechanisms  Investigator-Initiated Research Projects –R01 Research Project Grant –R03 Small Grant –R21 Exploratory/Developmental Grant Clinical Trials –R34 Clinical Trial Planning Grant –U01 Clinical Trial Implementation Grant –mR01 Milestone-driven Clinical Trial Implementation Grant  Solicited Research Activities See NIAID Home Page ( for Funding Opportunity Announcements  Research Resources 5

6

Research Opportunities: Examples of Research Resources  Filariasis Research Reagent Resource Center (FR3)  Schistosomiasis Resource Center  International Collaborative Network for the Study of Human Helminth Co-infections  HIV/AIDS Clinical Trials Networks 7

For More Information:  NIAID Home Page 8

9